Zura Bio launches global Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa

Zura Bio Ltd

TibuSHIELD will enroll ~180 adults with moderate-to-severe HS across US, Canada, and Europe.
Study is 28-week, double-blind, placebo-controlled, with 16-week primary efficacy and 12-week safety follow-up, plus optional OLE.
Primary endpoint: percent change in total abscess and nodule count at Week 16; secondary endpoints include HiSCR50/75.
Topline results for primary endpoint expected in Q3 2026.
Tibulizumab targets both BAFF and IL-17A pathways; still investigational, not FDA-approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.